Ameriprise Financial Inc. Sells 25,168 Shares of Repligen Co. (NASDAQ:RGEN)

Ameriprise Financial Inc. lessened its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 929,090 shares of the biotechnology company's stock after selling 25,168 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.66% of Repligen worth $133,733,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Ballentine Partners LLC grew its holdings in Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after acquiring an additional 72 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 81 shares during the period. GAMMA Investing LLC increased its holdings in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares during the period. Louisiana State Employees Retirement System increased its holdings in Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after purchasing an additional 100 shares during the period. Finally, Utah Retirement Systems raised its position in Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 100 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RGEN has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Monday. TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Evercore ISI assumed coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Repligen Stock Performance

Shares of RGEN opened at $126.88 on Thursday. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The company has a market cap of $7.12 billion, a PE ratio of -248.78, a P/E/G ratio of 4.54 and a beta of 1.21. The stock has a 50-day moving average of $136.21 and a 200-day moving average of $145.61. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same quarter last year, the firm posted $0.28 earnings per share. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. On average, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.